Access the full text.
Sign up today, get DeepDyve free for 14 days.
Dedrick (1978)
1Cancer Treat Rep, 62
F. Elekonawo, W. Eden, W. Plas, R. Ewalds, L. Jong, A. Bremers, P. Hemmer, N. Kok, S. Kruijff, A. Aalbers, P. Reuver (2020)
Effect of intraperitoneal chemotherapy concentration on morbidity and survivalBJS Open, 4
C. Bakkers, F. Erning, K. Rovers, S. Nienhuijs, J. Burger, V. Lemmens, A. Aalbers, N. Kok, D. Boerma, A. Brandt, P. Hemmer, W. Grevenstein, P. Reuver, P. Tanis, J. Tuynman, I. Hingh (2020)
Long-term survival after hyperthermic intraperitoneal chemotherapy using mitomycin C or oxaliplatin in colorectal cancer patients with synchronous peritoneal metastases: A nationwide comparative study.European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
A. Prada-Villaverde, J. Esquivel, A. Lowy, M. Markman, T. Chua, J. Pelz, D. Baratti, J. Baumgartner, R. Berri, P. Bretcha-Boix, M. Deraco, G. Flores-Ayala, O. Glehen, A. Gómez-Portilla, S. González-Moreno, M. Goodman, E. Halkia, S. Kusamura, Mecker Moller, G. Passot, M. Pocard, G. Salti, A. Sardi, M. Senthil, J. Spiliotis, J. Torres‐Melero, K. Turaga, R. Trout (2014)
The American Society of Peritoneal Surface Malignancies evaluation of HIPEC with Mitomycin C versus Oxaliplatin in 539 patients with colon cancer undergoing a complete cytoreductive surgeryJournal of Surgical Oncology, 110
Leung (2017)
144Eur J Surg Oncol, 43
F. Quénet, D. Elias, L. Roca, D. Goéré, L. Ghouti, M. Pocard, O. Facy, C. Arvieux, G. Lorimier, D. Pezet, F. Marchal, V. Loi, P. Meeus, B. Juzyna, H. forges, J. Paineau, O. Glehen (2021)
Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial.The Lancet. Oncology
A. González-Martín, B. Pothuri, I. Vergote, R. Christensen, W. Graybill, M. Mirza, C. Mccormick, D. Lorusso, P. Hoskins, G. Freyer, K. Baumann, K. Jardon, A. Redondo, R. Moore, C. Vulsteke, R. O’Cearbhaill, B. Lund, F. Backes, P. Barretina-Ginesta, A. Haggerty, M. Rubio-Pérez, M. Shahin, G. Mangili, W. Bradley, I. Bruchim, K. Sun, I. Malinowska, Yong Li, D. Gupta, B. Monk (2019)
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.Obstetrical & Gynecological Survey
Cashin (2013)
533Eur J Clin Pharmacol, 69
I. Ubink, Ana Bolhaqueiro, S. Elias, Daniëlle Raats, Alexander Constantinides, N. Peters, E. Wassenaar, I. Hingh, K. Rovers, W. Grevenstein, M. Laclé, G. Kops, I. Rinkes, O. Kranenburg (2019)
Organoids from colorectal peritoneal metastases as a platform for improving hyperthermic intraperitoneal chemotherapyThe British Journal of Surgery, 106
Sugarbaker (2016)
29J Gastrointest Oncol, 7
Vergote (2010)
943N Engl J Med, 363
P. Krawczyk, Berina Eppink, J. Essers, J. Stap, H. Rodermond, H. Odijk, A. Zelensky, C. Bree, L. Stalpers, M. Buist, Thomas Soullié, J. Rens, H. Verhagen, M. O’Connor, N. Franken, T. Hagen, R. Kanaar, J. Aten (2011)
Mild hyperthermia inhibits homologous recombination, induces BRCA2 degradation, and sensitizes cancer cells to poly (ADP-ribose) polymerase-1 inhibitionProceedings of the National Academy of Sciences, 108
V. Bastiaenen, C. Klaver, N. Kok, J. Wilt, I. Hingh, A. Aalbers, D. Boerma, A. Bremers, J. Burger, E. Duyn, P. Evers, W. Grevenstein, P. Hemmer, E. Madsen, P. Snaebjornsson, J. Tuynman, M. Wiezer, M. Dijkgraaf, J. Bilt, P. Tanis (2019)
Second and third look laparoscopy in pT4 colon cancer patients for early detection of peritoneal metastases; the COLOPEC 2 randomized multicentre trialBMC Cancer, 19
J. Esquivel, A. Lowy, M. Markman, T. Chua, J. Pelz, D. Baratti, J. Baumgartner, R. Berri, P. Bretcha-Boix, M. Deraco, G. Flores-Ayala, O. Glehen, A. Gómez-Portilla, S. González-Moreno, M. Goodman, E. Halkia, S. Kusamura, Mecker Moller, G. Passot, M. Pocard, G. Salti, A. Sardi, M. Senthil, John Spilioitis, J. Torres‐Melero, K. Turaga, R. Trout (2014)
The American Society of Peritoneal Surface Malignancies (ASPSM) Multiinstitution Evaluation of the Peritoneal Surface Disease Severity Score (PSDSS) in 1,013 Patients with Colorectal Cancer with Peritoneal CarcinomatosisAnnals of Surgical Oncology, 21
I. Kyriazanos, V. Kalles, A. Stefanopoulos, J. Spiliotis, F. Mohamed (2016)
Operating personnel safety during the administration of Hyperthermic Intraperitoneal Chemotherapy (HIPEC).Surgical oncology, 25 3
Kyriazanos (2016)
308Surg Oncol, 25
Koole (2019)
4587Cancer, 125
Hoppenot (2020)
1780Ann Surg Oncol, 27
Spiliotis (2015)
1570Ann Surg Oncol, 22
Armstrong (2019)
896J Natl Compr Canc Netw, 17
C. Klaver, D. Wisselink, C. Punt, P. Snaebjornsson, J. Crezee, A. Aalbers, A. Brandt, A. Bremers, J. Burger, H. Fabry, F. Ferenschild, S. Festen, W. Grevenstein, P. Hemmer, I. Hingh, N. Kok, G. Musters, L. Schoonderwoerd, J. Tuynman, A. Ven, H. Westreenen, M. Wiezer, D. Zimmerman, A. Zweeden, M. Dijkgraaf, P. Tanis (2019)
Adjuvant hyperthermic intraperitoneal chemotherapy in patients with locally advanced colon cancer (COLOPEC): a multicentre, open-label, randomised trial.The lancet. Gastroenterology & hepatology
Zivanovic (2015)
699Int J Cancer, 136
M. Bushati, K. Rovers, A. Sommariva, P. Sugarbaker, David Morris, Y. Yonemura, Claudio Quadros, S. Somashekhar, W. Ceelen, Pierre Dubé, Yan Li, V. Verwaal, O. Glehen, P. Piso, J. Spiliotis, M. Teo, S. González-Moreno, P. Cashin, K. Lehmann, M. Deraco, B. Moran, I. Hingh (2018)
The current practice of cytoreductive surgery and HIPEC for colorectal peritoneal metastases: Results of a worldwide web-based survey of the Peritoneal Surface Oncology Group International (PSOGI).European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 44 12
R. Dedrick, C. Myers, Bungay Pm, V. Devita (1978)
Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer.Cancer treatment reports, 62 1
R. Auer, D. Sivajohanathan, J. Biagi, J. Conner, E. Kennedy, T. May (2020)
Indications for hyperthermic intraperitoneal chemotherapy with cytoreductive surgery: a clinical practice guideline.Current oncology, 27 3
A González-Martín, B Pothuri, I Vergote (2019)
Niraparib in patients with newly diagnosed advanced ovarian cancerN Engl J Med, 381
Moore (2018)
2495N Engl J Med, 379
Lim (2017)
5520J Clin Oncol, 35
A. Kuijpers, M. Hauptmann, A. Aalbers, S. Nienhuijs, I. Hingh, M. Wiezer, B. Ramshorst, R. Ginkel, K. Havenga, V. Verwaal (2016)
Cytoreduction and hyperthermic intraperitoneal chemotherapy: The learning curve reassessed.European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 42 2
J. Segelman, F. Granath, T. Holm, M. Machado, H. Mahteme, A. Martling (2012)
Incidence, prevalence and risk factors for peritoneal carcinomatosis from colorectal cancerBritish Journal of Surgery, 99
M. Flessner, R. Dedrick, J. Schultz (1985)
A distributed model of peritoneal-plasma transport: analysis of experimental data in the rat.The American journal of physiology, 248 3 Pt 2
B Sadeghi, C Arvieux, O Glehen (2000)
Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective studyCancer, 88
Howell (1982)
845Ann Intern Med, 97
S. Koole, J. Kieffer, K. Sikorska, J. Leeuwen, Hendrik Schreuder, R. Hermans, I. Hingh, J. Velden, H. Arts, M.A.P.C. Ham, A. Aalbers, V. Verwaal, K. Vijver, G. Sonke, W. Driel, N. Aaronson (2019)
Health-related quality of life after interval cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with stage III ovarian cancer.European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
Multhoff (1999)
1627Exp Hematol, 27
Bushati (2018)
1942Eur J Surg Oncol, 44
Ubink (2018)
e204Br J Surg, 105
Joan Walker, D. Armstrong, Helen Huang, J. Fowler, K. Webster, R. Burger, D. Clarke‐Pearson (2006)
Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study.Gynecologic oncology, 100 1
S. Howell, C. Pfeifle, W. Wung, R. Olshen, W. Lucas, J. Yon, M. Green (1982)
Intraperitoneal cisplatin with systemic thiosulfate protection.Annals of internal medicine, 97 6
D. Goéré, A. Souadka, M. Faron, A. Cloutier, B. Viaña, C. Honoré, F. Dumont, D. Elias (2015)
Extent of Colorectal Peritoneal Carcinomatosis: Attempt to Define a Threshold Above Which HIPEC Does Not Offer Survival Benefit: A Comparative StudyAnnals of Surgical Oncology, 22
J. Esquivel, A. Averbach (2012)
Laparoscopic Cytoreductive Surgery and HIPEC in Patients with Limited Pseudomyxoma Peritonei of Appendiceal OriginGastroenterology Research and Practice, 2012
Prada-Villaverde (2014)
779J Surg Oncol, 110
RL Dedrick, MF Flessner (1997)
Pharmacokinetic problems in peritoneal drug administration: tissue penetration and surface exposureJ Natl Cancer Inst, 89
R. Helderman, Daan Löke, H. Kok, A. Oei, P. Tanis, N. Franken, J. Crezee (2019)
Variation in Clinical Application of Hyperthermic Intraperitoneal Chemotherapy: A ReviewCancers, 11
G. Multhoff, L. Mizzen, C. Winchester, C. Milner, S. Wenk, G. Eissner, H. Kampinga, B. Laumbacher, Judith Johnson (1999)
Heat shock protein 70 (Hsp70) stimulates proliferation and cytolytic activity of natural killer cells.Experimental hematology, 27 11
Robert Dedrick, Michael Flessner (1997)
Pharmacokinetic problems in peritoneal drug administration: tissue penetration and surface exposure.Journal of the National Cancer Institute, 89 7
S. Koole, Christiaan Lieshout, W. Driel, Evi Schagen, K. Sikorska, J. Kieffer, J. Leeuwen, H. Schreuder, R. Hermans, I. Hingh, J. Velden, H. Arts, L. Massuger, A. Aalbers, V. Verwaal, K. Vijver, N. Aaronson, H. Tinteren, G. Sonke, W. Harten, V. Retèl (2019)
Cost Effectiveness of Interval Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy in Stage III Ovarian Cancer on the Basis of a Randomized Phase III Trial.Obstetrical & Gynecological Survey
Los (1992)
1252Cancer Res, 52
SN Koole, C van Lieshout, WJ van Driel (2019)
Cost effectiveness of interval cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in stage III ovarian cancer on the basis of a randomized phase III trialJ Clin Oncol, 37
Tewari (2015)
1460J Clin Oncol, 33
K. Rovers, C. Bakkers, G. Simkens, J. Burger, S. Nienhuijs, G. Creemers, A. Thijs, A. Brandt-Kerkhof, E. Madsen, N. Ayez, N. Boer, E. Meerten, J. Tuynman, M. Kusters, N. Sluiter, H. Verheul, H. Vliet, M. Wiezer, D. Boerma, E. Wassenaar, M. Los, C. Hunting, A. Aalbers, N. Kok, K. Kuhlmann, H. Boot, M. Chalabi, S. Kruijff, L. Been, R. Ginkel, D. Groot, R. Fehrmann, J. Wilt, A. Bremers, P. Reuver, S. Radema, K. Herbschleb, W. Grevenstein, A. Witkamp, M. Koopman, N. Mohammad, E. Duyn, W. Mastboom, L. Mekenkamp, J. Nederend, M. Lahaye, P. Snaebjornsson, C. Verhoef, H. Laarhoven, A. Zwinderman, J. Bouma, O. Kranenburg, Iris Erve, R. Fijneman, M. Dijkgraaf, P. Hemmer, C. Punt, P. Tanis, I. Hingh (2019)
Perioperative systemic therapy and cytoreductive surgery with HIPEC versus upfront cytoreductive surgery with HIPEC alone for isolated resectable colorectal peritoneal metastases: protocol of a multicentre, open-label, parralel-group, phase II-III, randomised, superiority study (CAIRO6)BMC Cancer, 19
Sadeghi (2000)
358Cancer, 88
Spratt (1980)
256Cancer Res, 40
Koole (2019)
2041J Clin Oncol, 37
D. Hompes, D. Hompes, A. D'Hoore, A. Wolthuis, S. Fieuws, B. Mirck, S. Bruin, V. Verwaal (2014)
The use of Oxaliplatin or Mitomycin C in HIPEC treatment for peritoneal carcinomatosis from colorectal cancer: A comparative studyJournal of Surgical Oncology, 109
V. Verwaal, S. Ruth, E. Bree, Gooike Sloothen, H. Tinteren, H. Boot, F. Zoetmulder (2003)
Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 21 20
D. Goéré, O. Glehen, F. Quénet, J. Guilloit, J. Bereder, G. Lorimier, É. Thibaudeau, L. Ghouti, A. Pinto, J. Tuech, R. Kianmanesh, M. Carretier, F. Marchal, C. Arvieux, C. Brigand, P. Meeus, P. Rat, S. Durand-Fontanier, P. Mariani, Z. Lakkis, V. Loi, N. Pirró, C. Sabbagh, M. Texier, D. Elias (2020)
Second-look surgery plus hyperthermic intraperitoneal chemotherapy versus surveillance in patients at high risk of developing colorectal peritoneal metastases (PROPHYLOCHIP-PRODIGE 15): a randomised, phase 3 study.The Lancet. Oncology
A. Wright, K. Bohlke, D. Armstrong, M. Bookman, W. Cliby, R. Coleman, D. Dizon, J. Kash, L. Meyer, K. Moore, A. Olawaiye, J. Oldham, R. Salani, D. Sparacio, W. Tew, I. Vergote, M. Edelson (2016)
Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline.Obstetrical & Gynecological Survey
Kuijpers (2016)
244Eur J Surg Oncol, 42
Koole (2020)
1928Int J Gynecol Cancer, 30
Dedrick (1997)
480J Natl Cancer Inst, 89
Timmermans (2018)
31Eur J Cancer, 88
Armstrong (2006)
34N Engl J Med, 354
V. Leung, Ya Huo, W. Liauw, David Morris, David Morris (2017)
Oxaliplatin versus Mitomycin C for HIPEC in colorectal cancer peritoneal carcinomatosis.European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 43 1
N. Colombo, N. Colombo, C. Sessa, A. Bois, J. Ledermann, W. McCluggage, I. McNeish, P. Morice, S. Pignata, I. Ray-Coquard, I. Vergote, T. Baert, I. Belaroussi, A. Dashora, S. Olbrecht, F. Planchamp, D. Querleu (2019)
ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent diseaseInternational Journal of Gynecological Cancer, 29
F. Bray, J. Ferlay, I. Soerjomataram, R. Siegel, Lindsey Torre, A. Jemal (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesCA: A Cancer Journal for Clinicians, 68
Bray (2018)
394CA Cancer J Clin, 68
Joan Walker, M. Brady, L. Wenzel, G. Fleming, Helen Huang, P. DiSilvestro, K. Fujiwara, D. Alberts, Wenxin Zheng, K. Tewari, D. Cohn, M. Powell, L. Le, S. Davidson, H. Gray, P. Rose, C. Aghajanian, T. Myers, A. Secord, S. Rubin, R. Mannel (2019)
Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 37 16
T. Freedman, H. Lynch, S. Lemon, S. Tinley, J. Lynch, P. Watson (1997)
Psychologic Aspects of Cancer Genetic Testing: A Research Update for Clinicians
DK Armstrong, B Bundy, L Wenzel (2006)
Intraperitoneal cisplatin and paclitaxel in ovarian cancerN Engl J Med, 354
Wright (2015)
2841J Clin Oncol, 33
Verwaal (2003)
3737J Clin Oncol, 21
Quénet (2021)
256Lancet Oncol, 22
Klaver (2017)
224Colorectal Dis, 19
Kwakman (2016)
1102Ann Surg, 263
W. Eden, Niels Kok, K. Woensdregt, A. Huitema, Henk Boot, A. Aalbers (2017)
Safety of intraperitoneal Mitomycin C versus intraperitoneal oxaliplatin in patients with peritoneal carcinomatosis of colorectal cancer undergoing cytoreductive surgery and HIPEC.European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 44 2
Goéré (2020)
1147Lancet Oncol, 21
D. Baratti, S. Kusamura, F. Pietrantonio, M. Guaglio, M. Niger, M. Deraco (2016)
Progress in treatments for colorectal cancer peritoneal metastases during the years 2010-2015. A systematic review.Critical reviews in oncology/hematology, 100
S. Koole, W. Driel, G. Sonke (2019)
Hyperthermic intraperitoneal chemotherapy for ovarian cancer: The heat is onCancer, 125
D Tewari, JJ Java, R Salani (2015)
Long-term survival advantage and prognostic factors associated with intraperitoneal chemotherapy treatment in advanced ovarian cancer: a Gynecologic Oncology Group studyJ Clin Oncol, 33
J. Spratt, R. Adcock, M. Muskovin, W. Sherrill, J. McKeown (1980)
Clinical delivery system for intraperitoneal hyperthermic chemotherapy.Cancer research, 40 2
Elekonawo (2020)
293BJS Open, 4
Wright (2016)
3460J Clin Oncol, 34
M. Ceresoli, Apollonia Verrengia, G. Montori, L. Busci, F. Coccolini, L. Ansaloni, L. Frigerio (2018)
Effect of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy on relapse pattern in primary epithelial ovarian cancer: a propensity score based case-control studyJournal of Gynecologic Oncology, 29
DK Armstrong, RD Alvarez, JN Bakkum-Gamez (2019)
NCCN guidelines insights: ovarian cancer, version 1.2019: featured updates to the NCCN guidelinesJ Natl Compr Canc Netw, 17
R. Nagourney, S. Evans, P. Tran, Adam Nagourney, P. Sugarbaker (2020)
Colorectal cancer cells from patients treated with FOLFOX or CAPOX are resistant to oxaliplatin.European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
Doubeni (2016)
937Am Fam Physician, 93
P. Cashin, H. Ehrsson, I. Wallin, P. Nygren, H. Mahteme (2012)
Pharmacokinetics of cisplatin during hyperthermic intraperitoneal treatment of peritoneal carcinomatosisEuropean Journal of Clinical Pharmacology, 69
P. Harter, A. Reuss, J. Sehouli, L. Chiva, A. Bois (2017)
Brief Report About the Role of Hyperthermic Intraperitoneal Chemotherapy in a Prospective Randomized Phase 3 Study in Recurrent Ovarian Cancer From Spiliotis et al.International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 27 2
PH Sugarbaker (2003)
Peritonectomy proceduresSurg Oncol Clin N Am, 12
I. Ubink, W. Eden, P. Snaebjornsson, Niels Kok, J. Kuik, W. Grevenstein, M. Laclé, Joyce Sanders, R. Fijneman, S. Elias, I. Rinkes, A. Aalbers, O. Kranenburg (2018)
Histopathological and molecular classification of colorectal cancer and corresponding peritoneal metastasesBritish Journal of Surgery, 105
Flessner (1985)
F413Am J Physiol, 248
J. Spiliotis, E. Halkia, E. Lianos, N. Kalantzi, A. Grivas, E. Efstathiou, S. Giassas (2015)
Cytoreductive Surgery and HIPEC in Recurrent Epithelial Ovarian Cancer: A Prospective Randomized Phase III StudyAnnals of Surgical Oncology, 22
CA Doubeni, AR Doubeni, AE Myers (2016)
Diagnosis and management of ovarian cancerAm Fam Physician, 93
De-Kun Li, Marian Willinger, Diana Petitti, R. Odouli, Liyan Liu, Howard Hoffman (2005)
Use of a dummy (pacifier) during sleep and risk of sudden infant death syndrome (SIDS): population based case-control studyBMJ : British Medical Journal, 332
I. Torres, C. Litterst, A. Guarino (1978)
Transport of model compounds across the peritoneal membrane in the rat.Pharmacology, 17 6
P. Disaia (1987)
Diagnosis and management of ovarian cancer.Hospital practice, 22 4
D. Armstrong, R. Alvarez, J. Bakkum-Gamez, L. Barroilhet, K. Behbakht, A. Berchuck, J. Berek, Lee-may Chen, M. Cristea, M. DeRosa, A. ElNaggar, D. Gershenson, H. Gray, A. Hakam, A. Jain, C. Johnston, C. Iii, Joyce Liu, H. Mahdi, D. Matei, M. McHale, K. McLean, D. O’Malley, R. Penson, S. Percac-Lima, E. Ratner, S. Remmenga, P. Sabbatini, T. Werner, Emese Zsíros, J. Burns, Anita Engh (2019)
NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019.Journal of the National Comprehensive Cancer Network : JNCCN, 17 8
C. Group (2020)
The Chicago Consensus on Peritoneal Surface Malignancies: Management of Ovarian NeoplasmsAnnals of Surgical Oncology, 27
R. Kwakman, Anne Schrama, J. Olmen, René Otten, E. Klerk, E. Cuba, G. Kazemier, E. Velde (2016)
Clinicopathological Parameters in Patient Selection for Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Cancer Metastases: A Meta-analysisAnnals of Surgery, 263
P. Vaart, N. Vange, F. Zoetmulder, A. Goethem, O. Tellingen, W. Huinink, J. Beijnen, H. Bartelink, A. Begg (1998)
Intraperitoneal cisplatin with regional hyperthermia in advanced ovarian cancer: pharmacokinetics and cisplatin-DNA adduct formation in patients and ovarian cancer cell lines.European journal of cancer, 34 1
Koole (2021)
101Eur J Surg Oncol, 47
M. Lim, Suk-Joon Chang, H. Yoo, B. Nam, R. Bristow, Sang-Yoon Park (2017)
Randomized trial of hyperthermic intraperitoneal chemotherapy (HIPEC) in women with primary advanced peritoneal, ovarian, and tubal cancer.Journal of Clinical Oncology, 35
PM Krawczyk, B Eppink, J Essers (2011)
Mild hyperthermia inhibits homologous recombination, induces BRCA2 degradation, and sensitizes cancer cells to poly (ADP-ribose) polymerase-1 inhibitionProc Natl Acad Sci U S A, 108
B. Hildebrandt, P. Wust, O. Ahlers, A. Dieing, G. Sreenivasa, T. Kerner, R. Felix, H. Riess (2002)
The cellular and molecular basis of hyperthermia.Critical reviews in oncology/hematology, 43 1
Auer (2020)
146Curr Oncol, 27
S. Koole, Ruby Stein, K. Sikorska, D. Barton, L. Perrin, D. Brennan, O. Zivanovic, B. Mosgaard, A. Fagotti, Emmanuel Colombo, G. Sonke (2020)
Primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) for FIGO stage III epithelial ovarian cancer: OVHIPEC-2, a phase III randomized clinical trialInternational Journal of Gynecological Cancer, 30
Sugarbaker (2003)
703Surg Oncol Clin N Am, 12
Torres (1978)
330Pharmacology, 17
Segelman (2012)
699Br J Surg, 99
González-Martín (2019)
2391N Engl J Med, 381
Esquivel (2014)
4195Ann Surg Oncol, 21
Klaver (2019)
761Lancet Gastroenterol Hepatol, 4
Rovers (2019)
390BMC Cancer, 19
Ubink (2019)
1404Br J Surg, 106
AA Wright, A Cronin, DE Milne (2015)
Use and effectiveness of intraperitoneal chemotherapy for treatment of ovarian cancerJ Clin Oncol, 33
D. Tewari, J. Java, R. Salani, D. Armstrong, M. Markman, T. Herzog, B. Monk, J. Chan (2015)
Long-term survival advantage and prognostic factors associated with intraperitoneal chemotherapy treatment in advanced ovarian cancer: a gynecologic oncology group study.Obstetrical & Gynecological Survey
Baratti (2016)
209Crit Rev Oncol Hematol, 100
Koole (2020)
888Int J Gynecol Cancer, 30
J. Dyson, D. Simmons, J. Daniel, J. McLaughlin, P. Quirke, C. Bird (1986)
Kinetic and Physical Studies of Cell Death Induced By Chemotherapeutic Agents Or HyperthermiaCell Proliferation, 19
van Baal (2017)
95Tissue Cell, 49
P. Sugarbaker (1996)
Peritonectomy procedures.Cancer treatment and research, 82
Franko (2016)
1709Lancet Oncol, 17
W. Driel, S. Koole, K. Sikorska, J. Leeuwen, H. Schreuder, R. Hermans, I. Hingh, J. Velden, H. Arts, L. Massuger, A. Aalbers, V. Verwaal, J. Kieffer, K. Vijver, H. Tinteren, N. Aaronson, G. Sonke (2018)
Hyperthermic Intraperitoneal Chemotherapy in Ovarian CancerThe New England Journal of Medicine, 378
Razenberg (2016)
e41Clin Colorectal Cancer, 15
J. Franko, Q. Shi, J. Meyers, T. Maughan, R. Adams, M. Seymour, L. Saltz, C. Punt, M. Koopman, C. Tournigand, N. Tebbutt, E. Díaz-Rubio, J. Souglakos, A. Falcone, B. Chibaudel, V. Heinemann, J. Moen, A. Gramont, D. Sargent, A. Grothey (2016)
Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database.The Lancet. Oncology, 17 12
J. Baal, K. Vijver, R. Nieuwland, C. Noorden, W. Driel, A. Sturk, G. Kenter, L. Rikkert, Ckm Lok (2017)
The histophysiology and pathophysiology of the peritoneum.Tissue & cell, 49 1
B. Brücher, P. Piso, V. Verwaal, J. Esquivel, Marcello Derraco, Y. Yonemura, S. González-Moreno, Jorg Pelz, A. Königsrainer, M. Ströhlein, E. Levine, D. Morris, D. Bartlett, O. Glehen, A. Garofalo, A. Nissan (2012)
Peritoneal Carcinomatosis: Cytoreductive Surgery and HIPEC–-Overview and BasicsCancer Investigation, 30
van Driel (2018)
230N Engl J Med, 378
K. Jaaback, N. Johnson (2006)
Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer.The Cochrane database of systematic reviews, 1
Bakkers (2020)
1902Eur J Surg Oncol, 46
Bois (2020)
6000J Clin Oncol, 38
O. Zivanovic, A. Abramian, M. Kullmann, C. Fuhrmann, C. Coch, T. Hoeller, H. Ruehs, M. Keyver-Paik, C. Rudlowski, Stefan Weber, N. Kiefer, M. Poelcher, T. Thiesler, B. Rostamzadeh, M. Mallmann, N. Schaefer, M. Permantier, S. Latten, J. Kalff, J. Thomale, U. Jaehde, W. Kuhn (2014)
HIPEC ROC I: A phase i study of cisplatin administered as hyperthermic intraoperative intraperitoneal chemoperfusion followed by postoperative intravenous platinum‐based chemotherapy in patients with platinum‐sensitive recurrent epithelial ovarian cancerInternational Journal of Cancer, 136
JE Dyson, DM Simmons, J Daniel, JM McLaughlin, P Quirke, CC Bird (1986)
Kinetic and physical studies of cell death induced by chemotherapeutic agents or hyperthermiaCell Tissue Kinet, 19
Harter (2017)
246Int J Gynecol Cancer, 27
Hildebrandt (2002)
33Crit Rev Oncol Hematol, 43
Hompes (2014)
527J Surg Oncol, 109
van de Vaart (1998)
148Eur J Cancer, 34
S. Koole, L. Bruijs, C. Fabris, K. Sikorska, M. Engbersen, J. Leeuwen, H. Schreuder, R. Hermans, J. Velden, H. Arts, M. Ham, P. Dam, P. Vuylsteke, M. Lahaye, G. Sonke, W. Driel (2020)
Central radiology assessment of the randomized phase III open-label OVHIPEC-1 trial in ovarian cancerInternational Journal of Gynecological Cancer, 30
AD Bois, J Sehouli, I Vergote (2020)
Randomized phase III study to evaluate the impact of secondary cytoreductive surgery in recurrent ovarian cancer: final analysis of AGO DESKTOP III/ENGOT-ov20J Clin Oncol, 38
A. Wright, A. Cronin, Dana Milne, M. Bookman, R. Burger, D. Cohn, M. Cristea, J. Griggs, N. Keating, C. Levenback, G. Mantia-Smaldone, U. Matulonis, L. Meyer, J. Niland, J. Weeks, D. O’Malley (2015)
Use and Effectiveness of Intraperitoneal Chemotherapy for Treatment of Ovarian Cancer.Obstetrical & Gynecological Survey
van Eden (2018)
220Eur J Surg Oncol, 44
Gerrit Los, O. Smals, Marianne Vugt, Martin Vlist, L. Engelse, J. Mcvie, H. Pinedo (1992)
A rationale for carboplatin treatment and abdominal hyperthermia in cancers restricted to the peritoneal cavity.Cancer research, 52 5
M. Timmermans, G. Sonke, K. Vijver, M. Aa, R. Kruitwagen (2018)
No improvement in long-term survival for epithelial ovarian cancer patients: A population-based study between 1989 and 2014 in the Netherlands.European journal of cancer, 88
Dyson (1986)
311Cell Tissue Kinet, 19
A. Bois, J. Sehouli, I. Vergote, G. Ferron, A. Reuss, W. Meier, S. Greggi, P. Jensen, F. Selle, F. Guyon, C. Pomel, F. Lécuru, R. Zang, E. Åvall-Lundqvist, J. Kim, J. Ponce, F. Raspagliesi, S. Ghaem-Maghami, A. Reinthaller, P. Harter (2020)
Randomized phase III study to evaluate the impact of secondary cytoreductive surgery in recurrent ovarian cancer – final analysis of AGO DESKTOP III/ENGOT- ov20Geburtshilfe und Frauenheilkunde, 80
Á. Arjona-Sánchez, P. Barrios, E. Boldó-Roda, B. Camps, J. Carrasco-Campos, V. Martín, A. García-Fadrique, A. Gutiérrez-Calvo, R. Morales, G. Ortega-Pérez, E. Pérez-Viejo, A. Prada-Villaverde, J. Torres‐Melero, E. Vicente, P. Villarejo-Campos, J. Sánchez-Hidalgo, Á. Casado-Adam, R. García-Martin, M. Medina, T. Caro, C. Villar, E. Aranda, M. Cano-Osuna, C. Díaz-López, E. Torres-Tordera, F. Briceño-Delgado, S. Rufián-Peña (2018)
HIPECT4: multicentre, randomized clinical trial to evaluate safety and efficacy of Hyperthermic intra-peritoneal chemotherapy (HIPEC) with Mitomycin C used during surgery for treatment of locally advanced colorectal carcinomaBMC Cancer, 18
K. Moore, N. Colombo, G. Scambia, Byoung-Gie Kim, A. Oaknin, M. Friedlander, A. Lisyanskaya, A. Floquet, A. Leary, G. Sonke, C. Gourley, Susana Banerjee, A. Oza, A. González-Martín, C. Aghajanian, W. Bradley, C. Mathews, Joyce Liu, E. Lowe, R. Bloomfield, P. DiSilvestro (2018)
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian CancerThe New England Journal of Medicine, 379
Oei (2015)
165Radiat Oncol, 10
Krawczyk (2011)
9851Proc Natl Acad Sci U S A, 108
C. Klaver, Hannah Groenen, D. Morton, Søren Laurberg, W. Bemelman, P. Tanis (2017)
Recommendations and consensus on the treatment of peritoneal metastases of colorectal origin: a systematic review of national and international guidelinesColorectal Disease, 19
P. Sugarbaker, K. Speeten (2016)
Surgical technology and pharmacology of hyperthermic perioperative chemotherapy.Journal of gastrointestinal oncology, 7 1
L. Razenberg, Y. Gestel, V. Lemmens, I. Hingh, G. Creemers (2016)
Bevacizumab in Addition to Palliative Chemotherapy for Patients With Peritoneal Carcinomatosis of Colorectal Origin: A Nationwide Population-Based Study.Clinical colorectal cancer, 15 2
A. Oei, L. Vriend, J. Crezee, N. Franken, P. Krawczyk (2015)
Effects of hyperthermia on DNA repair pathways: one treatment to inhibit them allRadiation Oncology (London, England), 10
Brücher (2012)
209Cancer Invest, 30
Walker (2006)
27Gynecol Oncol, 100
AA Wright, K Bohlke, DK Armstrong (2016)
Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology clinical practice guidelineJ Clin Oncol, 34
I. Vergote, C. Tropé, F. Amant, G. Kristensen, T. Ehlen, N. Johnson, R. Verheijen, M. Burg, Á. Lacave, P. Panici, G. Kenter, A. Casado, C. Mendiola, C. Coens, L. Verleye, G. Stuart, S. Pecorelli, N. Reed (2010)
Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer.The New England journal of medicine, 363 10
Walker (2019)
1380J Clin Oncol, 37
Goéré (2015)
2958Ann Surg Oncol, 22
ImportanceThe peritoneal surface is a common site of disease in ovarian and colorectal cancer. Peritoneal metastases carry a poor prognosis, despite maximal therapeutic efforts, including surgical removal of tumor deposits and intravenous chemotherapy. Hyperthermic intraperitoneal chemotherapy (HIPEC) is a single intraoperative procedure that delivers chemotherapy directly into the abdominal cavity, leading to high intracellular drug concentration at the peritoneal surface. This review describes the current knowledge regarding the mechanism of action, safety, and efficacy of HIPEC in the treatment of peritoneal metastases from epithelial ovarian and colorectal cancers and explores current knowledge gaps. ObservationsToxic effects of HIPEC are limited. Evidence from a randomized trial shows improved recurrence-free and overall survival after HIPEC in patients with ovarian cancer who are ineligible for primary cytoreductive surgery (CRS). The effect of HIPEC for patients with ovarian cancer undergoing primary CRS or CRS for recurrent disease has not yet been determined, and results of ongoing trials must be awaited. A recent study in patients with peritoneal metastases from colorectal cancer did not show a benefit of HIPEC when added to perioperative chemotherapy. Conclusions and RelevanceBased on available evidence, various international guidelines include the option to add HIPEC to interval CRS for patients with stage III ovarian cancer. The role of HIPEC in colorectal cancer is less well defined. Future studies will need to tailor patient selection, timing, and optimal regimens of HIPEC to improve the effectiveness of this specialized treatment in ovarian, colorectal, and other tumor types.
JAMA Oncology – American Medical Association
Published: Aug 6, 2021
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.